Streetbeat News

Price Targets

HOOD

Morgan Stanley analyst Michael Cyprys has reiterated an Equal-Weight rating on Robinhood Markets (NASDAQ:HOOD) and maintained a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:09 pm

RVLV

Morgan Stanley analyst Lauren Schenk has reiterated an Equal-Weight rating on Revolve Group (NYSE:RVLV) and maintained a $19 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:08 pm

REZI

Morgan Stanley analyst Erik Woodring has maintained an Equal-Weight rating on Resideo Technologies (NYSE:REZI) and lowered the price target from $21 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:06 pm

RGA

Morgan Stanley analyst Nigel Dally has reiterated an Equal-Weight rating on Reinsurance Gr (NYSE:RGA) and maintained a $160 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:04 pm

REGN

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $897 to $912.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:01 pm

VC

In the last quarter, Visteon (NASDAQ:VC) received mixed analyst ratings with 1 bullish, 2 somewhat bullish, 2 indifferent, and 2 somewhat bearish. The company has an average 12-month price target of $157.57, which has increased by 4.21% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 7:00 pm

RRR

Morgan Stanley analyst Stephen Grambling has maintained an Overweight rating on Red Rock Resorts (NASDAQ:RRR) but lowered the price target from $55 to $54.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 6:59 pm

QTWO

Morgan Stanley analyst James Faucette has maintained an Equal-Weight rating on Q2 Holdings (NYSE:QTWO) and raised the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 6:58 pm

PTCT

Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a $47 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 6:57 pm

PRLD

Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on Prelude Therapeutics (NASDAQ:PRLD) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 6:46 pm